Inadequate and delayed characterization of cutaneous reactions for US Food and Drug Administration-approved oncologic drugs from 2011-2020 leading to medication discontinuation

J Am Acad Dermatol. 2021 Nov;85(5):1351-1352. doi: 10.1016/j.jaad.2020.10.047. Epub 2020 Oct 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Drug Approval
  • Drug-Related Side Effects and Adverse Reactions*
  • Humans
  • Medical Oncology
  • Pharmaceutical Preparations*
  • United States
  • United States Food and Drug Administration

Substances

  • Pharmaceutical Preparations